Product Portfolio Concentration

Goal of the analysis:

The goal is to quantify how concentrated revenue, margin, and growth are across products in the portfolio, and to evaluate the risk, resilience, and cost-to-serve implications of that concentration. Executives use this analysis to make resource allocation decisions (marketing, capex, inventory), guide portfolio strategy (where to invest, what to prune), and manage operational risk (dependence on a few SKUs, supplier exposure). Balanced concentration supports focus and scale; excessive concentration creates fragility, while excessive fragmentation increases complexity and erodes profitability.

Data required:

• Sales and profitability data:
  • Transactional sales by product/SKU: revenue, units, date (daily/weekly/monthly), channel, region, customer segment.
  • Gross margin dollars and margin % by product (COGS, landed costs, rebates, returns, write-offs).
  • Net price realized, discounts, promotions, and returns/credits applied to the correct period.
• Product master and hierarchy:
  • SKU, product name, product family/portfolio grouping, platform/module relationships.
  • Lifecycle stage (incubate/launch/grow/mature/decline), launch date, end-of-life (EOL) date.
  • Substitution/cannibalization mappings and successor/predecessor relations.
• Supply, sourcing, and capacity signals:
  • Primary/secondary suppliers per product, supplier concentration, lead times.
  • Manufacturing capacity by product line, utilization, changeover costs.
  • Inventory positions and stockout records that could bias concentration.
• Pricing and promo levers:
  • List and floor prices, historical price changes, promo calendar, trade spend.
  • Bundling/attach rates for accessories or services.
• Customer and channel metadata (for risk overlays):
  • Top customers per product and cross-product overlap (to assess correlated exposure).
  • Channel mix (ecommerce, direct, retail, distributor) per product.
• Historical and benchmark data:
  • At least 24 months of history for trend/seasonality.
  • Internal benchmarks (prior periods, top-quartile business units) and any external benchmarks.

Detailed step-by-step instruction on how to conduct the analysis:

1. Define scope and metrics. Choose the unit of analysis (SKU vs. product family), geography, channels, and time window (e.g., last 12 months rolling). Select primary metric(s): revenue share, gross margin share, and optionally growth contribution and volume share.
2. Extract and prepare data. Pull sales and margin data from ERP/BI (e.g., SAP, Oracle, NetSuite, Snowflake, Power BI/Tableau) and product master data from PIM/MDM. Cleanse for duplicate SKUs, harmonize product codes, align returns and credits to the correct product and period, and map SKUs to families/platforms.
3. Aggregate performance by product. For each product/SKU and period:
   • Compute revenue, gross margin dollars, units, growth vs. prior period.
   • Calculate each product’s share: share_i = product metric / total portfolio metric for the scope.
   • Rank products descending by share and compute cumulative share.
4. Calculate concentration indicators.
   • CRn (Concentration Ratio): Sum of shares of top n products (e.g., CR3, CR5, CR10).
   • HHI (Herfindahl-Hirschman Index): HHI = sum of squared shares across all products (use shares as decimals). Optionally normalize by number of products: nHHI = (HHI – 1/N) / (1 – 1/N).
   • Pareto metrics: Identify the % of products contributing 80% of revenue/margin and vice versa (80/20 check).
   • Gini or entropy (optional): For a more nuanced view of distribution inequality.
5. Segment and slice. Repeat the calculations by product family, region, channel, price tier, and lifecycle stage. Compare SKU-level vs. family-level concentration to observe platform dependence.
6. Trend analysis. Compute the metrics over time (monthly rolling 12-month views):
   • Trend CR3/CR5 and HHI; flag inflections following major launches or stockouts.
   • Assess stability: month-over-month share volatility of the top 5 products.
7. Overlay operational and risk signals.
   • For top-contributing products, show supplier count, single-sourcing flags, capacity utilization, and stockout frequency.
   • Map customer overlap for top products to gauge correlated demand risk.
8. Scenario and sensitivity modeling.
   • Downside: Remove 10–30% of revenue from the top product (supply disruption) and estimate portfolio impact; include substitution assumptions to other SKUs.
   • Rationalization: Eliminate bottom x% of SKUs by revenue and model demand recapture and margin impact.
   • Growth: Add planned launches with forecasted revenue to project future concentration.
9. Validate and reconcile. Ensure product totals reconcile to financial statements, margins are plausible, and anomalies (e.g., negative margins) are investigated.
10. Synthesize insights. Summarize where dependence is highest, which segments drive concentration, whether trends are improving or deteriorating, and the operational risks and opportunities.

Format of the output of analysis:

• Executive summary table with CR3/CR5/CR10, HHI, 80/20 stats, and trend deltas.
• Pareto charts ranking products by revenue and by margin with cumulative share curves.
• Time-series line charts of HHI and CR3/CR5 over the last 24 months.
• Bubble chart (x: revenue share, y: margin %, size: growth) for top 20 products.
• Heatmaps by region/channel/lifecycle stage showing concentration metrics.
• Risk overlay view for top products: supplier count, capacity utilization, stockout rate.
• Scenario slides quantifying downside from a top-product shock and upside from tail rationalization or launches.

How to interpret results:

• High concentration (high CR3/CR5, high HHI): Indicates dependence on few products. Benefits: focus, scale economies, clearer positioning. Risks: revenue fragility, supply/quality shocks, pricing pressure. If top products are also single-sourced or capacity-constrained, risk is amplified.
• Low concentration (low CRs, low HHI): Suggests a fragmented portfolio. Benefits: diversification and resilience. Risks: complexity costs (inventory, changeovers), diluted marketing, and high tail with low margin or negative profit.
• Revenue vs. margin concentration: If revenue is concentrated but margin is not, leaders may be traffic drivers with low profitability. If margin is more concentrated than revenue, prioritize protecting those high-profit SKUs.
• Segment differences: Higher concentration in certain regions/channels can indicate fit or execution differences. Lifecycle skew toward mature SKUs may show underperforming innovation; heavy reliance on new products may indicate volatility and ramp risk.
• Benchmark lens: Compare to internal/external benchmarks. A CR3 materially above peers or rising HHI without commensurate risk mitigation is concerning. Trend-wise, gradual concentration after a successful launch can be healthy; sharp spikes often reflect stockouts or discontinuations.

Steps a company can take to improve on this measure:

• Portfolio strategy and product actions:
  • If concentration is too high: accelerate adjacent variants, bundles, and add-ons; expand into new price tiers; diversify channels/regions; develop services/recurring revenue to spread dependence.
  • If fragmentation is too high: rationalize low-velocity SKUs, platform and modularize to reduce complexity, focus marketing on winners, enforce minimum velocity/margin thresholds.
  • Manage cannibalization explicitly when launching successors; maintain healthy core coverage while onboarding innovation.
• Process and policy changes:
  • Strengthen stage-gate with clear kill criteria and post-launch reviews.
  • Embed portfolio concentration KPIs in S&OP; set guardrails for tail growth and reliance on top SKUs.
  • Mitigate operational risk for top products: dual sourcing, strategic safety stocks, flexible capacity, quality controls.
• Data, systems, and tooling:
  • Establish robust product hierarchies and SKU-level profitability (landed cost, rebates, returns).
  • Automate concentration dashboards (CRn, HHI, Pareto) in BI; integrate supply risk overlays.
  • Implement demand-substitution and cannibalization models to improve scenario accuracy.
• Capability building and governance:
  • Create a cross-functional portfolio council (Product, Finance, Supply Chain, Sales) to review concentration monthly.
  • Align incentives to portfolio outcomes (e.g., profitable growth, SKU discipline) rather than pure top-line.
  • Train PMs on pricing, attach strategies, and rationalization playbooks; run controlled experiments to shift mix.

Benchmark comparisons:

General benchmarks:

• CR3 (top 3 products’ revenue share): diversified portfolios often 30–50%; concentrated portfolios 60%+.
• CR5: diversified 45–70%; concentrated 75–90%.
• HHI (based on product revenue shares):
  • < 1,500: relatively diversified
  • 1,500–2,500: moderately concentrated
  • > 2,500: highly concentrated
• Pareto: many portfolios see ~20% of SKUs drive ~80% of revenue; top performers ensure bottom 30–40% of SKUs contribute positive gross margin or are pruned.

Segment- or industry-specific benchmarks:

• Consumer electronics: CR3 often 50–70% at SKU level; HHI 1,800–3,000 due to flagship products.
• Enterprise/SaaS: top product may be 40–70% of ARR; modules/add-ons reduce concentration over time.
• Industrial distribution/MRO: broad catalog; CR10 ~60–80% with lower HHI, but margin may be concentrated in a subset.
• CPG and apparel: seasonality creates transient spikes; family-level concentration moderate, SKU-level high; tail management critical.

Building internal benchmarks when external are scarce:

• Compare concentration across countries, channels, and business units; use top quartile internal performers as targets.
• Track pre- and post-launch concentration for major introductions to define acceptable arcs.
• Establish target ranges by lifecycle stage (e.g., mature families CR3 45–60%; growth families may be higher short term).